Inhaled corticosteroids and bone health

Open Respiratory Medicine Journal

Volumn 8, Issue , 2014, Pages 85-92

  Chee, Carolyn ^a   Sellahewa, Luckni ^b   Pappachan, Joseph M ^c  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b ROYAL DERBY HOSPITAL   (United Kingdom)

^c MANOR HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonate; Bone mineral density (BMD); Glucocorticoid induced osteoporosis (GIO); ICS induced bone disease; Inhaled corticosteroids (ICS)

Indexed keywords

ALENDRONIC ACID; BUDESONIDE; CALCIUM; CORTICOSTEROID; DENOSUMAB; IBANDRONIC ACID; NEDOCROMIL; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; ROMOSOZUMAB; VITAMIN D; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BODY HEIGHT; BONE DENSITY; BONE DISEASE; BONE NECROSIS; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG INDUCED DISEASE; DRUG SAFETY; FRACTURE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; URINARY TRACT INFECTION;

EID: 84928888940     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401408010085     Document Type: Article

References (74)

1. Raissy HH, Kelly HW, Harkins M, Szefler SJ. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 2013; 187: 798-803.
2. Kelly HW. Potential adverse effects of inhaled corticosteroids. J Allergy Clin Immunol 2003; 112: 469-78.
3. Buehring B, Viswanathan R, Binkley N, Busse W. Glucocorticoidinduced osteoporosis: an update on effects and management. J Allergy Clin Immunol 2013; 132: 1019-30.
4. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26: 229-38.
5. McCormick RK. Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility. Altern Med Rev 2007; 12: 113-45.
6. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377(9773): 1276-87.
7. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-86.
8. Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. Int J Med Sci 2012; 9: 825-32.
9. Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of the deleterious effects on bone. J Clin Invest 1998; 102: 274-82.
10. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012; 41: 595-611.
11. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008; 149: 1793-801.
12. Georgiou KR, Hui SK, Xian CJ. Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells 2012; 1: 205-24.
13. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor a increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem 2011; 286: 44326-35.
14. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010; 11: 517-31.
15. Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006; 116: 2152-60.
16. Lane NE, Yao W, Balooch M, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Min Res 2006; 21: 466-76.
17. Xia X, Kar R, Gluhak-Heinrich J, et al. Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res 2010; 25: 2479-88.
18. Bollet AJ, Black R, Bumin JJ. Major undesirable side-effects resulting from prednisolone and prednisone. JAMA 1955; 157: 459-63.
19. Heiman WG, Freiberger RH. Avascular necrosis of the femoral and humeral heads after high-dosage corticosteroid therapy. N Engl J Med 1960; 263: 672-5.
20. Weinstein RS. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365: 62-70.
21. Khan N, Abbas AM, Almukhtar RM, Khan A. Prevalence and predictors of low bone mineral density in males with ulcerative colitis. J Clin Endocrinol Metab 2013; 98: 2368-75.
22. LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990; 8: 39-51.
23. van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arth Rheum 2003; 48: 3224-29.
24. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835-41.
25. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoidinduced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-28.
26. Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010; 9: 147-61.
27. Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008; 11: 43-58.
28. Levis S, Theodore G. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm 2012; 18(4 Suppl B): S1-15.
29. Gonnelli S, Caffarelli C, Nuti R. Obesity and fracture risk. Clin Cases Miner Bone Metab 2014; 11: 9-14.
30. Klop C, Welsing PM, Cooper C, et al. Mortality in British hip fracture patients, 2000-2010: A population-based retrospective cohort study. Bone 2014; 66: 171-77.
31. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoidinduced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-28.
32. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine 2012; 41: 183-90.
33. Nash JJ, Nash AG, Leach ME, Poetker DM. Medical malpractice and corticosteroid use. Otolaryngol Head Neck Surg 2011; 144: 10-15.
34. Drescher W, Schlieper G, Floege J, Eitner F. Steroid-related osteonecrosis-an update. Nephrol Dial Transplant 2010; 26: 1728-31.
35. Ko JY, Wang FS, Wang CJ, Wong T, Chou WY, Tseng SL. Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone 2010; 46: 584-91.
36. Youm YS, Lee SY, Lee SH. Apoptosis in the osteonecrosis of the femoral head. Clin Orthop Surg 2010; 2: 250-55.
37. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. Endocrinology 2000; 85: 2907-12.
38. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699-708.
39. Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E; Osteoporotic Fractures in Men (MrOS) Research Group. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int 2010; 21: 1341-49.
40. Sidoroff VH, Ylinen MK, Kröger LM, Kröger HP, Korppi MO. Inhaled corticosteroids and bone mineral density at school age: a follow-up study after early childhood wheezing. Pediatr Pulmonol 2013 Dec 17. doi: 10.1002/ppul.22968. [Epub ahead of print].
41. Kisielinski K, Niedhart C, Schneider U, Niethard FU. Osteonecrosis 15 years after femoral neck fracture and long-term low-dose inhaled corticosteroid therapy. Joint Bone Spine 2004; 71: 237-39.
42. Drigo I, Saccari A, Barbi E, Bartoli F, Decorti G, Ventura A. Osteonecrosis of the hip after short courses of oral and inhaled steroids in a child with an increased number of glucocorticoid receptors. Eur J Pediatr 2006; 165: 913-15.
43. Kaviani N, Bukberg P, Manessis A, Yen V, Young I. Iatrogenic osteoporosis, bilateral HIP osteonecrosis, and secondary adrenal suppression in an HIV-infected man receiving inhaled corticosteroids and ritonavir-boosted highly active antiretroviral therapy. Endocr Pract 2011; 17: 74-78.
44. Pollett S, Graves B, Richards B, MacLeod C. Avascular necrosis in a HIV patient receiving ritonavir and inhaled fluticasone. Int J STD AIDS 2014; 25: 458-60.
45. Anderson WJ, McFarlane LC, Lipworth BJ. Prospective follow-up of novel markers of bone turnover in persistent asthmatics exposed to low and high doses of inhaled ciclesonide over 12 months. J Clin Endocrinol Metab 2012; 97: 1929-36.
46. Szefler S, Weiss S, and Tonascia J. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343: 1054-63.
47. Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367: 904-12.
48. Pruteanu AI, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: doseresponse effects on growth. Cochrane Database Syst Rev 2014; 7: CD009878.
49. Xiaomei W, Hang X, Lingling L, Xuejun L. Bone Metabolism Status and Associated Risk Factors in Elderly Patients with Chronic Obstructive Pulmonary Disease (COPD). Cell Biochem Biophys 2014; 70: 129-34.
50. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006; 39: 253-59.
51. Zalavras CG, Lieberman JR. Osteonecrosis of the femoral head: evaluation and treatment. J Am Acad Orthop Surg 2014; 22: 455-64.
52. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-26.
53. Hansen KE, Wilson HA, Zapalowski C, Fink HA, Minisola S, Adler RA. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 2011; 26: 1989-96.
54. Fuerst T, Wu C, Genant HK, et al. Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting. Osteoporos Int 2009; 20: 1199-205.
55. Schousboe JT, Vokes T, Broy SB, et al. Vertebral Fracture Assessment: the 2007 ISCD Official Positions. J Clin Densitom 2008; 11: 92-108.
56. Mazzantini M, Di Munno O. Glucocorticoid-induced osteoporosis: 2013 update. Reumatism 2014; 66(2): 144-52.
57. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24: 23-57.
58. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9: 1-160.
59. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-78.
60. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008; 24: 237-45.
61. McGreevy C, Williams D. Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf 2011; 2: 159-72.
62. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-39.
63. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65 [Erratum, N Engl J Med 2009; 361: 1914.
64. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010; 69: 872-75.
65. Nardone V, D'Asta F, Brandi ML. Pharmacological management of osteogenesis. Clinics (Sao Paulo) 2014; 69: 438-46.
66. Aljubran SA, Whelan GJ, Glaum MC, Lockey RF. Osteoporosis in the at-risk asthmatic. Allergy 2014 Jul 21. doi: 10.1111/all.12438. [Epub ahead of print].
67. McClung MR, Grauer A, Boonen S. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-20.
68. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. J Bone Jt Surg Am 2005; 87: 2155-59.
69. Agarwala S, Shah SB. Ten-year follow-up of avascular necrosis of femoral head treated with alendronate for 3 years. J Arthroplast 2011; 26: 1128-34.
70. Sigua-Rodriguez EA, da Costa Ribeiro R, de Brito AC, Alvarez-Pinzon N, de Albergaria-Barbosa JR. Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent 2014; 2014: 192320.
71. Lau EM, Woo J, Chan YH, Li M. Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone 2001; 29: 506-10.
72. Herrala J, Puolijoki H, Liippo K, Raitio M, Impivaara O, Tala E, Nieminen MM. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone 1998; 22: 577-82.
73. Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM; Research Committee of the British Thoracic Society. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 2004; 59: 761-68.
74. Kasayama S, Fujita M, Goya K, Yamamoto H, Fujita K, Morimoto Y, Kawase I, Miyatake A. Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. Metabolism 2005; 54: 85-90.